JMA’s Nakagawa Pushes Price Cuts Even on Non-100 Billion Yen Products, Eyes Other Hep C Drugs

JMA Vice President Toshio Nakagawa Toshio Nakagawa, vice president of the Japan Medical Association (JMA), is calling for revising the so-called “ huge-seller” re-pricing rule introduced last year, setting his sights on hepatitis C drugs similar to Harvoni (ledipasvir +...read more